Comprehensive transcriptomic analysis in wild-type and ATM knockout lung cancer cells: Influence of cisplatin on

Ayşegül Varol1, Sabine M Klauck2, Susan P Lees-Miller3

  • 1Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University-Mainz, 55128, Mainz, Germany.

Insights

Genetic mutations in ATM impair cancer drug effectiveness. Targeting ATM with CRISPR/Cas9 enhances cisplatin therapy by activating cell death pathways, offering new avenues for personalized cancer treatment.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Genetic mutations and impaired DNA repair mechanisms in cancer contribute to tumor progression and chemoresistance.
  • Cisplatin efficacy is often limited by these genetic alterations.
  • Combination therapy presents a promising strategy to overcome drug resistance.

Purpose of the Study:

  • To investigate the role of DNA double-strand break repair proteins in cancer drug resistance.
  • To identify key proteins and pathways involved in cisplatin resistance.
  • To explore novel therapeutic strategies for overcoming chemoresistance.

Main Methods:

  • Analysis of overall survival and mutation data across over 7,500 tumors from 23 cancer types.
  • Examination of 23 double-strand break repair proteins, focusing on ATM (ataxia-telangiectasia mutated).
  • CRISPR/Cas9 gene editing to study ATM mutations and their effects on cisplatin response, including microarray analysis.

Main Results:

  • ATM mutations were found to be the most frequent among the studied DNA repair proteins.
  • ATM knockout enhanced cisplatin cytotoxicity by inducing oxidative stress-induced senescence and necroptosis.
  • ATM knockout promoted senescence via increased reactive oxygen species (ROS) and decreased NRF2 expression, revealing a regulatory interplay.

Conclusions:

  • ATM is a critical factor in cancer's response to cisplatin.
  • Targeting ATM and oxidative stress-induced senescence, potentially through CRISPR/Cas9, offers a novel strategy to enhance combination therapy.
  • Integrating genetic profiling with advanced tools can lead to personalized cancer treatments tailored to individual mutational landscapes.